BiotechTube
NeuPulse

NeuPulse

London, United Kingdom· Est.
neupulse.co
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $500K

Overview

NeuPulse is pioneering a wearable neuromodulation device for Tourette Syndrome, representing a significant shift from pharmacological interventions. The technology, based on median nerve stimulation, has shown promising results in UK clinical trials, with participants reporting substantial reductions in tic severity. The company is targeting a commercial launch in Great Britain in 2026, followed by international expansion, positioning itself to address a significant unmet need in the neurostimulation market. Its business model combines a device sale with a recurring software subscription.

Tourette Syndrome

Technology Platform

Wearable wrist device delivering transcutaneous electrical stimulation of the median nerve to modulate brain circuits associated with tic generation.

Funding History

1
Total raised:$500K
Grant$500K

Opportunities

Addresses a significant unmet need for non-pharmacological treatment in Tourette Syndrome with a patient-controlled, wearable device.
The subscription-based model offers recurring revenue, and the platform technology has potential for expansion into other neurological disorders.

Risk Factors

Heavily reliant on successful regulatory approval for 2026 launch; clinical and real-world efficacy must be broadly proven.
Faces commercialization risks executing a direct-to-consumer model and competition from existing therapies and other neuromodulation approaches.

Competitive Landscape

Competes against established treatments like behavioral therapy (CBIT) and generic medications, as well as invasive deep brain stimulation for severe cases. May face future competition from other non-invasive neuromodulation devices (e.g., transcranial magnetic stimulation) being explored for Tourette's.

More companies in United Kingdom →